Atara Biotherapeutics announced a second proposed offering of its common stock in 2018, offering $150 million worth of shares at $43.10 per share. The stock has skyrocketed more than 135 percent since the first of the year, ending Feb. 27 at $42.55 per share. The company raised around $131 million in January with a public…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
